Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study

BACKGROUND: Tenofovir alafenamide (TAF) may be preferable to other nucleos(t)ide analogues (NA) regarding outcomes against chronic hepatitis B virus (HBV) infection. AIMS: To evaluate the longer term virological/biochemical effectiveness of TAF and the renal safety of sequential therapy to TAF in re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Eiichi, Nakamuta, Makoto, Koyanagi, Toshimasa, Ooho, Aritsune, Furusyo, Norihiro, Kajiwara, Eiji, Dohmen, Kazufumi, Kawano, Akira, Satoh, Takeaki, Takahashi, Kazuhiro, Azuma, Koichi, Yamashita, Nobuyuki, Yamashita, Naoki, Sugimoto, Rie, Amagase, Hiromasa, Kuniyoshi, Masami, Ichiki, Yasunori, Morita, Chie, Kato, Masaki, Shimoda, Shinji, Nomura, Hideyuki, Hayashi, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Tenofovir Alafenamide in Chronic Hbv Infection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543913/
https://www.ncbi.nlm.nih.gov/pubmed/35735794
http://dx.doi.org/10.1111/apt.17107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543913/
https://www.ncbi.nlm.nih.gov/pubmed/35735794
http://dx.doi.org/10.1111/apt.17107

Ejemplares similares